Researchers from Leiden University will develop a
new approach to study the biomarkers of Alzeimer’s disease. This
approach focusses on the molecular messengers of the cells. The project,
led by Thomas Hankemeier and coordinated by Yuliya Shakalisava (Leiden
Academic Centre for Drug Research, LACDR), received a funding of 800.000
euros from EuroNanoMed.
Messengers from the brain
The project is called EXIT, with stands for
EXosomes
Isolation
Tool.
It will develop a novel analytical device to investigate the molecular
messengers from the brain (exosomes) in samples from patients with
Alzheimer’s disease. Exosomes are nanosized membranous vesicles which
recently appeared to play an important role in the remote communication
between cells. Furthermore, it was found exosomes are able to pass the
blood-brain barrier. Exosomes carry various proteins, RNA and
metabolites and are present in all body fluids. This makes them a
promising resource for diagnostic and etiologic research.
Novel device
Together with SINTEF AS, a Norwegian nanotechnology research
institute, the researchers of LACDR will develop a novel nanofluidic
concentration device. This device will allow to concentrate and separate
exosomes from blood and cerebrospinal fluid. Exosome research is a new
and very rapidly developing area. Industrial partner HansaBioMed
(Estonia) will bring in its invaluable expertise about this area to the
project. Finally, an analytical platform will be set up with the two
medical partners: Erasmus MC (the Netherlands) and FundaciĆ³ ACE (Spain).
This platform will be used to analyse samples of blood and
cerebrospinal fluid investigate the metabolic, proteomic, immunological
and transcriptional changes in the body caused by Alzheimer’s disease.
EuroNanoMed
EuroNanoMed
is a platform for funding agencies and ministries that are engaged with
the application of nanotechnology to medicine and healthcare. Here
national and regional funding programmes can join together with the goal
of creating and funding collaborative research and innovation projects
that convert research in nanotechnology into practical gains in
medicine. EuroNanoMed supports multidisciplinary and translational
research and innovation projects that cover: regenerative medicine,
diagnostics and targeted delivery systems.
SOURCE: universiteitleiden.n
Comments
Post a Comment